



Figure 4: The BETi compounds hinder short-term proliferation in ERMS. RD and RMS-YM cells were treated with respective EC_{50} concentrations of the BETi compounds in technical triplicates and were allowed to grow until the vehicle-treated cells reached confluency. Cells were plated to achieve 30% confluence at the time of drug dosing. Confluence was quantified from phase contrast images taken every 4 hours using the IncuCyte ZOOM in 96-well plate format. Those time-points where the instrument was out-of-focus due to the low contrast appearance of the cells were excluded. \pm SD is indicated. Abbreviations: BET, I-BET151; BMS, BMS-986158; PLX, PLX51107.